Compare AVLN & HLIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | HLIT |
|---|---|---|
| Founded | N/A | 1988 |
| Country | United States | United States |
| Employees | N/A | 559 |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2026 | 1996 |
| Metric | AVLN | HLIT |
|---|---|---|
| Price | $33.84 | $12.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 175.5K | ★ 1.5M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.73 |
| Revenue Next Year | N/A | $18.36 |
| P/E Ratio | ★ N/A | $236.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.90 | $8.47 |
| 52 Week High | $40.17 | $17.68 |
| Indicator | AVLN | HLIT |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 43.96 |
| Support Level | $34.22 | $11.45 |
| Resistance Level | $40.08 | $12.48 |
| Average True Range (ATR) | 1.96 | 0.37 |
| MACD | -0.39 | -0.03 |
| Stochastic Oscillator | 9.89 | 17.57 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Harmonic Inc engaged in broadband access solutions that enable broadband operators to more efficiently and effectively deploy high-speed internet for data, voice, and video services for their customers and versatile and high-performance video delivery software, products, system solutions and services that enable its customers to efficiently create, prepare, store, playout and deliver a full range of high-quality broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets, and smartphones. It has two segments, Broadband which provides broadband access solutions and related services, and Others; and Video business provides video processing and production and playout solutions and services, and Others.